Pretreatment Level of Circulating Tumor Cells is Associated with Lymph Node Metastasis in Papillary Thyroid Carcinoma Patients with ≤ 55 Years Old

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Date 2025 Jan 29

PMID 39881336

Authors

Ming Yu

Jiaqin Deng

Yihua Gu

Yeqian Lai

Yuedong Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the relationship of pretreatment of circulating tumor cells (CTCs) and cervical lymph node metastasis (LNM) (central LNM (CLNM) and lateral LNM (LLNM)) in papillary thyroid carcinoma (PTC) patients with ≤ 55 years old.

Methods: Clinicopathological data (CTCs level, Hashimoto's thyroiditis, thyroid function, multifocal, tumor size, invaded capsule, clinical stage, and LNM) of 588 PTC patients with ≤ 55 years old were retrospectively collected. The relationship of CLNM, LLNM and the clinical features of patients was analyzed. Univariate and multivariate logistic regression analyses were used to evaluate the relationship between the CTCs and CLNM, LLNM.

Results: There were 273(46.4%) and 89(15.1%) patients with CLNM and LLNM, respectively. Patients with CLNM had higher proportions of multifocality, tumor size > 1 cm, invaded capsule, and positive CTCs level than those without (all p < 0.05). Patients with LLNM had higher proportions of multifocality, tumor size > 1 cm, and invaded capsule than those without (all p < 0.05). Logistic regression analysis showed that multifocality (odds ratio (OR): 1.821, 95% confidence interval (CI): 1.230-2.698, p = 0.003), tumor size > 1 cm (OR: 3.444, 95% CI: 2.296-5.167, p < 0.001), invaded capsule (OR: 1.699, 95% CI: 1.167-2.473, p = 0.006), and positive CTCs level (OR: 1.469, 95% CI: 1.019-2.118, p = 0.040) were independently associated with CLNM; and multifocality (OR: 2.373, 95% CI: 1.389-4.052, p = 0.002), tumor size > 1 cm (OR: 5.344, 95% CI: 3.037-9.402, p < 0.001), and invaded capsule (OR: 2.591, 95% CI: 1.436-4.674, p = 0.002) were independently associated with LLNM.

Conclusions: Preoperative CTCs positive was associated with CLNM in PTC patients with ≤ 55 years old, but not LLNM.

References

Zhang Z, Zhang X, Yin Y, Zhao S, Wang K, Shang M . Integrating BRAF mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma. BMC Cancer. 2022; 22(1):461. PMC: 9044661. DOI: 10.1186/s12885-022-09550-z. View

Heo D, Won H, Tae K, Kang Y, Jeon E, Ji Y . Clinical impact of coexistent chronic lymphocytic thyroiditis on central lymph node metastasis in low- to intermediate-risk papillary thyroid carcinoma: The MASTER study. Surgery. 2024; 175(4):1049-1054. DOI: 10.1016/j.surg.2023.12.023. View

White M, Holman D, Boehm J, Peipins L, Grossman M, Henley S . Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014; 46(3 Suppl 1):S7-15. PMC: 4544764. DOI: 10.1016/j.amepre.2013.10.029. View

Li T, Li H, Xue J, Miao J, Kang C . Shear wave elastography combined with gray-scale ultrasound for predicting central lymph node metastasis of papillary thyroid carcinoma. Surg Oncol. 2020; 36:1-6. DOI: 10.1016/j.suronc.2020.11.004. View

Pang J, Yang M, Li J, Zhong X, Shen X, Chen T . Interpretable machine learning model based on the systemic inflammation response index and ultrasound features can predict central lymph node metastasis in cN0T1-T2 papillary thyroid carcinoma. Gland Surg. 2023; 12(11):1485-1499. PMC: 10721554. DOI: 10.21037/gs-23-349. View

Zhong H, Zeng Q, Long X, Lai Y, Chen J, Wang Y . Risk factors analysis of lateral cervical lymph node metastasis in papillary thyroid carcinoma: a retrospective study of 830 patients. World J Surg Oncol. 2024; 22(1):162. PMC: 11191287. DOI: 10.1186/s12957-024-03455-w. View

Deng Z, Wu S, Wang Y, Shi D . Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022; 83:104237. PMC: 9440384. DOI: 10.1016/j.ebiom.2022.104237. View

Xu S, Cheng J, Wei B, Zhang Y, Li Y, Zhang Z . Development and validation of circulating tumor cells signatures for papillary thyroid cancer diagnosis: A prospective, blinded, multicenter study. Clin Transl Med. 2020; 10(4):e142. PMC: 7423182. DOI: 10.1002/ctm2.142. View

Liu Q, Pang W, Dong Y, Wang Z, Yu M, Huang X . Analysis of risk factors for lateral lymph node metastasis in papillary thyroid carcinoma: A retrospective cohort study. World J Otorhinolaryngol Head Neck Surg. 2022; 8(3):274-278. PMC: 9479478. DOI: 10.1016/j.wjorl.2021.01.002. View

10.

Qiu Z, Wei W, Sun Z, Shen C, Song H, Zhang X . Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. Cell Physiol Biochem. 2018; 48(2):718-730. DOI: 10.1159/000491898. View

11.

Du J, Li W, Zhao X, Shen C, Zhang X . Establishment of a predictive nomogram for differentiated thyroid cancer: an inpatient-based retrospective study. Endokrynol Pol. 2023; 74(6). DOI: 10.5603/ep.97087. View

12.

Tricoli J, Bleyer A . Adolescent and Young Adult Cancer Biology. Cancer J. 2018; 24(6):267-274. DOI: 10.1097/PPO.0000000000000343. View

13.

Yan X, Ma Z, Zhang Z, Xu D, Cai Y, Wu Z . The utility of sentinel Lymph node biopsy in the lateral neck in papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2022; 13:937870. PMC: 9357979. DOI: 10.3389/fendo.2022.937870. View

14.

Zheng W, Wang X, Rui Z, Wang Y, Meng Z, Wang R . Clinical features and therapeutic outcomes of patients with papillary thyroid microcarcinomas and larger tumors. Nucl Med Commun. 2019; 40(5):477-483. DOI: 10.1097/MNM.0000000000000991. View

15.

Kakudo K, Liu Z, Bai Y, Li Y, Kitayama N, Satoh S . How to identify indolent thyroid tumors unlikely to recur and cause cancer death immediately after surgery-Risk stratification of papillary thyroid carcinoma in young patients. Endocr J. 2021; 68(8):871-880. DOI: 10.1507/endocrj.EJ21-0018. View

16.

Gautam D, Clarke E, Roweth H, Smith M, Battinelli E . Platelets and circulating (tumor) cells: partners in promoting metastatic cancer. Curr Opin Hematol. 2024; 32(1):52-60. DOI: 10.1097/MOH.0000000000000852. View

17.

Li D, Li N, Ding Y . Epithelial-to-mesenchymal transition of circulating tumor cells and CD133 expression on predicting prognosis of thyroid cancer patients. Mol Clin Oncol. 2022; 17(3):141. PMC: 9403616. DOI: 10.3892/mco.2022.2574. View

18.

Feng J, Yang X, Wu B, Sun D, Jiang Y, Qu Z . Predictive factors for central lymph node and lateral cervical lymph node metastases in papillary thyroid carcinoma. Clin Transl Oncol. 2019; 21(11):1482-1491. DOI: 10.1007/s12094-019-02076-0. View

19.

Wang T, Sosa J . Thyroid surgery for differentiated thyroid cancer - recent advances and future directions. Nat Rev Endocrinol. 2018; 14(11):670-683. DOI: 10.1038/s41574-018-0080-7. View

20.

Wu X, Li B, Zheng C, He X . Predicting factors of lateral neck lymph node metastases in patients with papillary thyroid microcarcinoma. Medicine (Baltimore). 2019; 98(27):e16386. PMC: 6635253. DOI: 10.1097/MD.0000000000016386. View